| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | George A. Bray | Q20675488 |
| P2093 | author name string | Kaiser P | |
| Ryan DH | |||
| P2860 | cites work | Use and abuse of appetite-suppressant drugs in the treatment of obesity | Q40841386 |
| Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers | Q41938591 | ||
| Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo | Q44222626 | ||
| Barriers to the Treatment of Obesity | Q44454439 | ||
| Sibutramine in weight control: a dose-ranging, efficacy study | Q47425497 | ||
| The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation | Q48163276 | ||
| P921 | main subject | obesity | Q12174 |
| (RS)-sibutramine | Q424151 | ||
| P304 | page(s) | 553S-559S | |
| P577 | publication date | 1995-11-01 | |
| P1433 | published in | Obesity | Q15763232 |
| P1476 | title | Sibutramine: a novel new agent for obesity treatment | |
| P478 | volume | 3 Suppl 4 |
| Q77461223 | A model for chronic care of obesity through dietary treatment |
| Q24675513 | Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats |
| Q45188956 | Combined dietary and pharmacological weight management in obese hypopituitary patients |
| Q36673903 | Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. |
| Q35026535 | Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. |
| Q33684253 | Current concepts in the pharmacological management of obesity |
| Q39941666 | Effect of sibutramine HCl on cardiac hERG K+ channel |
| Q80353002 | Effects of sibutramine on gastric emptying, intestinal motility and rectal tone in dogs |
| Q36458423 | Emerging drugs for eating disorder treatment |
| Q38717129 | Epidemiology of Obesity and Pharmacologic Treatment Options |
| Q48147188 | Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist |
| Q43594329 | Influence of sibutramine on energy expenditure in African American women |
| Q54105933 | Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. |
| Q42057930 | Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat |
| Q34635461 | Leptin and the treatment of obesity: its current status |
| Q41284565 | Medicating the obese patient |
| Q36356847 | New drug policy in childhood obesity |
| Q35961441 | Pediatric obesity: parallels with addiction and treatment recommendations |
| Q44359168 | Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. |
| Q37265323 | Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. |
| Q30402685 | Prieurianin Causes Weight Loss in Diet-Induced Obese Mice and Inhibits Adipogenesis in Cultured Preadipocytes. |
| Q41611336 | Recent advances in the pharmacological control of energy balance and body weight. |
| Q43911362 | Regulation of body weight and carcass composition by sibutramine in rats |
| Q74238250 | Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine |
| Q44563283 | Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial |
| Q74272016 | Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid |
| Q41427028 | The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells |
| Q34330729 | The neuroendocrinology of childhood obesity |
| Q34381023 | The neuroendocrinology of obesity |
| Q35028643 | Thermogenic effects of sibutramine and its metabolites |
| Q34314208 | Treating obesity: a new target for prevention of coronary heart disease |
| Q41707222 | Update on the pharmacotherapy of obesity |
| Q34143853 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity |
| Q33998440 | Weight gain from novel antipsychotic drugs: need for action |
Search more.